Tim Seymour, CIO at Seymour Asset Management, tells "Worldwide Exchange" cannabis rescheduling to Schedule 3 could be transformative, with state approvals growing and an $80B market poised for more growth.
Breakdown
- Cannabis-related stocks and ETFs have surged after years of underperformance.
- Recent industry lobbying has led to increased attention in Washington and bipartisan support for regulatory changes. 44s
- The FDA has acknowledged medicinal benefits of cannabis, supporting potential rescheduling from Schedule I to III. 1m 28s
- State-level approval of cannabis markets has been consistent, but regulatory complexity remains for investors. 2m 35s
- The cannabis market is estimated at $80 billion, with growth opportunities despite ongoing legal challenges. 3m 12s